



Docket No.: EYE-010CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): David R. Guyer

Serial No: 10/786,491

Filed: February 25, 2004

For: METHODS FOR TREATING
OCULAR NEOVASCULAR
DISEASES

**CERTIFICATE OF MAILING
UNDER 37 CFR 1.8**

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date of Deposit: March 10, 2004

Type or Print Name of Person Mailing: Annya Dushine

Signature of Person Mailing

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56, 1.97 AND 1.98**

Mail Stop INFORMATION DISCLOSURE STATEMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is hereby submitted by Applicants in connection with the above-identified application. Pursuant to 37 C.F.R. §1.98(d), copies of documents C1-C20 cited on the PTO-1449 are provided herewith.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 U.S.C. § 102 or § 103.

In accordance with 37 C.F.R. §1.98(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed due under 37 C.F.R. §1.97(b) because this statement and Form PTO-1449 are being submitted before receipt of the first office action based on the merits of the above-identified patent application. However, the Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 503008. A duplicate copy of this is enclosed.

Dated: March 10, 2004

By:

Respectfully submitted,



Michael J. Rafa
Reg. No. 38,740
Customer No. 40336
Eyetech Pharmaceuticals Inc.
500 Seventh Avenue, 18th Floor
New York, NY 10018
212.997.9241 Telephone
212.997.9451 Facsimile

SHEET

Form PTO-1449 (Mod. 04)

U.S. Department of
Patent and TrademAtty. Docket No.
EYE-010CONSerial No.
10/786,491INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)

Applicant
David R. GuyerFiling Date
02/25/2004

Group

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. <i>Pharmaceutical Research</i> 2000;17(12):1503-10.
C2	Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. <i>Curr Top Microbiol Immunol</i> 1999;237:97-132.
C3	Ferrara N, Houck K, Jakeman L, et al. The vascular endothelial growth factor family of polypeptides. <i>J Cell Biochem</i> 1991;47:211-18.
C4	Folkman J, Shing Y. Angiogenesis. <i>J Biol Chem</i> 1992;267:10931-4.
C5	Funatsu H, Hidetoshi Y, Hidetaka N, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. <i>Am J Ophthalmol</i> 2002a;133(1):70-7.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Patent and Tradem.	Atty. Docket No. EYE-010CON	Serial No. 10/786,491
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant David R. Guyer	
		Filing Date 02/25/2004	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C6	Funatsu H, Yamashita H, Nakashini Y, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of subjects with proliferative diabetic retinopathy. <i>Br J Ophthalmol</i> 2002;86(3):311-15.	
C7	Hofman P, Harriet GT, Blaauwgeers MJ, et al. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. <i>Current Eye Research</i> 2000;21(2):637-45.	
C8	Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. <i>Br J Ophthalmol</i> 1997;81:154-62.	
C9	Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. <i>Arch Ophthalmol</i> 2002;120(3):338-46.	
C10	Kvanta A, Algreve PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. <i>Invest Ophthalmol Visual Sci</i> 1996;37:1929-34.	
C11	Leung DW, Cachianes G, Kuang W-J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. <i>Science</i> 1989;246:1306-9.	
C12	Lip P-L, Blann AD, Path MRCP, et al. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. <i>Ophthalmology</i> 2001;108:705-10.	
C13	Lopez PF, Sippi BD, Lambert MH, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. <i>Inves Ophthalmol Visual Sci</i> 1996;37:855-68.	
C14	Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). <i>Am J Pathol</i> 2000;156:1733-9.	
C15	Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier break down in early diabetes. <i>Invest Ophthalmol Vis Sci</i> 2001;42(10):2408-13.	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (Modified)		U.S. Department of Patent and Trademark	Atty. Docket No. EYE-010CON	Serial No. 10/786,491
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant David R. Guyer		
		Filing Date 02/25/2004	Group	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C16	Ruckman J, Green LS, Beeson J, et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF ₁₆₅). J Biol Chem 1998;273:20556-67.
	C17	Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219(4587):983-5.
	C18	Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 1996;37:1334-40.
	C19	Tucker CE, Chen L-S, Judkins MB, et al. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (EYE001) in rhesus monkeys. J Chromatog B. 1999;732:203-12.
	C20	Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of subjects with subretinal neovascularization. Br J Ophthalmol 1996;80:363-6.

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	